MHRA Data Portal — Proof of Concept
← Back to Orphan Designations

Detailed SMPC and OD register data for: ADCETRIS

Data as extracted from Orphan Designation Register

Product (OD)
ADCETRIS
PL number (OD)
PLGB 16189/0093
OD Designation ID (OD)
OD1
Active substance (OD)
brentuximab vedotin, Monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E

Data as extracted from SMPC. (PS: More information at bottom of the page)

Product (SMPC)
PL Number (SMPC)
Composition/ Active Substance (SMPC)
Dose form (SMPC)
Marketing Authorisation holder details (SMPC)

AI match to EMA Substance Dictionary

We analysed the SMPC composition text and searched for the closest equivalent in EMA's published substance dictionary. The suggested match and supporting details are shown below.

SMPC composition / active substance
Matched EMA substance
EMA SMS ID
Confidence
Higher confidence means the match is more likely to be correct.
Show AI rationale

Further information for:

Select a section below to read the detailed content extracted from the SMPC / Orphan Designation register.

OD Indication (OD)
ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory sALCL.
Full Designation Number(OD)
PLGB 16189/0093/OD1
Orphan Condition(OD)
Systemic anaplastic large cell lymphoma.
All Indications (SMPC)
All Contraindications (SMPC)
Warnings/Precautions (SMPC)
Interactions (SMPC)
Pregnancy/Lactation (SMPC)
Driving/Machines (SMPC)
Undesirable effects (SMPC)
Overdose (SMPC)
Shelf life (SMPC)
Storage (SMPC)
Container description (SMPC)
Handling/Disposal (SMPC)
SMPC_URL

Link to SMPC: Not available